Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | 06/30/2025 | 06/30/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -85.53% | -98.14% | 25.66% | 25.66% | 148.66% |
| Total Depreciation and Amortization | -- | -- | -- | -- | 304.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.33% | -868.09% | -66.45% | -66.45% | -231.25% |
| Change in Net Operating Assets | -185.17% | 100.93% | -221.76% | -221.76% | -33.58% |
| Cash from Operations | 59.05% | -75.24% | -203.88% | -203.88% | 19.81% |
| Capital Expenditure | 76.58% | 92.29% | 12.05% | 12.05% | -24.00% |
| Sale of Property, Plant, and Equipment | -18.33% | 242.96% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -24.94% | 45.18% | -174.97% | -174.97% | 124.43% |
| Other Investing Activities | 1,327.17% | -19.34% | 88.18% | 88.18% | 6.86% |
| Cash from Investing | 63.94% | -14.89% | -4.93% | -4.93% | 17.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -109.41% | -25.93% | 40.65% | 40.65% | -47.43% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -667.59% | -26.55% | 35.99% | 35.99% | -42.95% |
| Foreign Exchange rate Adjustments | 717.85% | 152.23% | -43.13% | -43.13% | 365.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 426.34% | -190.43% | -189.56% | -189.56% | 150.29% |